HTG Molecular to Present Corporate Overview at the SVB Leerink 9th Annual Global Healthcare Conference

HTG is focused on NGS-based molecular profiling.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Wednesday, February 19, 2020

Information

Tags:

Branches of biology, Medicine, Biology, Biomarkers, Biotechnology, Evidence-based medicine, Precision medicine, Systems biology

Geotags:

AZ, Us

Organisation:

HTG MOLECULAR DIAGNOSTICS, INC.

Summary

Key Points:

HTG is focused on NGS-based molecular profiling.
The companys proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount.
HTGs customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options.
Its mission is to empower precision medicine.

TUCSON, Ariz., Feb. 19, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that John Lubniewski, President and CEO, will present a corporate overview at the SVB Leerink 9^th Annual Global Healthcare Conference, taking place February 25-27, 2020 in New York City.

*HTG Molecular Presentation Details*
Date:	Wednesday, February 26
Time:	10:00 am Eastern Time
Webcast:	http://wsw.com/webcast/svbleerink34/htgm/

About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 430-7577
Email: [email protected]